Loading...
Please wait, while we are loading the content...
Similar Documents
Platelet mass has prognostic value in patients with myelodysplastic syndromes
| Content Provider | Scilit |
|---|---|
| Author | Bowles, Kristian M. Warner, Brian A. Baglin, Trevor P. |
| Copyright Year | 2006 |
| Description | Journal: British Journal of Haematology Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS |
| Ending Page | 200 |
| Starting Page | 198 |
| ISSN | 2573508X |
| e-ISSN | 13652141 |
| DOI | 10.1111/j.1365-2141.2006.06246.x |
| Journal | British Journal of Haematology |
| Issue Number | 2 |
| Volume Number | 135 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2006-10-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: British Journal of Haematology Myelodysplastic Syndromes Prognostic Factors |
| Content Type | Text |
| Resource Type | Article |